


## IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

T_4_mational	Application N	o. :	PC	T/EP2003/005224
	l Filing Date	:	19	May 2003 (19.05.2003)
		:	24	June 2002 (24.06.2002)
	e(s) Claimed	:	Hi	ltrud LINDENBLATT et al.
Applicant(s	) (DO/EO/US)			GOPEPTIDES AND ETHERIFIED
INFORM	ATION DISCI	OSURE ST	ATEMENT U	NDER 37 CFR §§ 1.56, 1.97 and 1.98
P ∩ Box 1	oner for Patents 1450 a, VA 22313-14			
Sir:				14 27 CEP 881 56 1.97
Th and 1.98	nis information o as follows:	lisclosure sta	ement is made	in accordance with 37 C.F.R. §§ 1.56, 1.97
Timing a	nd Fees			
⊠ U d	icologure statem	ient is ilieu.		ent is required for filing this information
	under 8 1	.53(d);		of a national application other than a CPA
C	within the	ree months	of the actual fi	ling date of the national phase of a PCT
1	before th	ne mailing of	a first substanti	ve office action (including after filing of an
	RCE). Under 37 C.F.R specified in 37	L § 1.97(c), th C.F.R. § 1.97	is information ( (b), but before	disclosure statement is filed after the periods the mailing date of:
		a final rejecti	on under 37 C.	F.R. 1.113;
		termination of	of prosecution,	e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);
		a notice of a	llowance under	37 C.F.R. § 1.311; and
	-		1	MERCK-2955



DT01 Rec'd PCT/FTC 23 DEC 2000

	is acco	impanied by:	DIOT NGC a FOIR E.	2 3 DEC	200
		the statement as specified in 37 C.l.	F.R. § 1.97(e) set out below;	OR	
		a check covering the fee of \$180.0	0 under 37 C.F.R. § 1.17(p).		
Und date	er 37 C.F of the fo	.R. § 1.97(d), this information disclo llowing actions which have not been	sure statement is filed after th		
		a final action under 37 C.F.R. § 1.	113;		
		termination of prosecution, e.g. E	x Parte Quayle, M.P.E.P § 6	i09(B)(2);	
+		a notice of allowance under 37 C.	F.R. § 1.311;		
AN	D is file	on or before payment of the issue	ee; AND is accompanied by	·:	
		the statement as specified in 37 C the fee of \$180.00 under 37 C.F.	C.F.R. § 1.97(e) as set forth	pelow, and	
Statement	s Under 3	37 C.F.R. 1.97(e)			
		Each item of information con statement was cited in a commun counterpart foreign application h months prior to the filing date of	aving a mailing date not mor	e than three	
		No item of information containe was cited in a communication fro foreign application, and to the after making reasonable inquiry information disclosure statemer in 37 C.F.R. § 1.56(c) more that the information disclosure states.	d in this information disclosu om a foreign patent office in a knowledge of the undersigr , no item of information cont it was known to any individua in three months prior to the f	re statement counterpart ned attorney ained in this al designated	t t ' s
Cited Ma	aterials				
C	an 14	opies of materials listed but not attack cestor application Serial No, 49 by the applicant; see 37 C.F.R. §	1.98(d).		
i	⊠ C	opies of materials listed but not atta- port dated <u>August 28, 2003</u> .	ched were cited in an interna		:h
	□ c	opies of the materials listed are attac	ched (except for the foregoin	ıg).	
		2		2D CIV 2055	



Non-English Language References
An English-language search report or equivalent paper.
A foreign-language search report from a foreign patent office is provided that is provided to the control of th
<ul> <li>X = document of particular relevance when it is taken alone</li> <li>Y = document of particular relevance when it is combined with another such</li> </ul>
document  A = document defining the general state of the art
O = non-written discussive P = intercalated document T = document cited to understand the theory or principle underlying the
T = document cited to discourse invention  E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date
D = cited in the application.  L = cited for another reason  L = cited for another reason  A vertical of member of same patent family
and a relevant information on foreign search report
Translation of other retorate the control of the co
Other Information
Payment of Fees Due (If Any):  A check for \$ covering the fee identified above is attached.
Please charge to Deposit Account No. 13-3402 \$ for the fee identified above.

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Ø

Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

nthony //elano, Reg. No. 27,969 Attorney Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza l 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333 Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-2955

Date: December 23, 2004

AJZ:ssr



PTO/SB/08A (08-00)

Please type a plus sign (+) inside this box

USNP of PCT/EP2003/005224 Substitute for form 1449A/PTO Application Number 19 May 2003 (19.05.2003) INFORMATION DISCLOSURE Filing Date Hittrud LINDENBLATT et al. STATEMENT BY APPLICANT First Named Inventor unknown Group Art Unit unknown Examiner Name (use as many sheets as necessary) MERCK-2955 Attorney Docket Number of

		U.S. Patent Docu		ATENT DOCUMENTS	Date of Publication of Citad Document
xaminer	Cita No.1	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document GOODMAN ET AL.	MM-DD-YYYY 12-14-1999 12-27-1994
	001	6001961 5376632	-	KONINGS ET AL.	12-27-1994
			-		
	+++				
	1-1				

			505	FIGI	N PATENT DOCUMENTS		Pages, Columns, Lines,	
		F	oreign Patent Document Kind	Code <sup>5</sup>	Name of Patentea or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
Examiner Initials*	Cite No.1	Office <sup>3</sup>	Number <sup>4</sup> (if k	(nown)	IANSSEN	08-08-1991		
	003	wo	9111200		PHARMACEUTICAL	07-04-1985		
	004	wo	8502767		PHARMACEUTICAL JONES ET AL.	10-26-2000		
	005	wo	0062793		JOILEG		-	+
		-					-	+
	-	+				-		
	+	-		_				

Examiner	Date Considered	p.e.o. Draw line through citation if not in conformance	
Examiner Signature  *EXAMINER: Initial if reference considered, whether or not citation is in core	nformance with MPE. pplicant.	the document, by the two-letter code	

EXAMINER: Initial if reference considered, whether or not citation is in conformant and not considered, include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>2</sup> Enter Office that issued the document, by the two-letter code (NVPO Standard ST.3). <sup>2</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>2</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>2</sup> Applicant is patent document. patent document. "Kind of document by the appropriate symbols as indicated on the document under Marku standard 51. To a possible, to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member, to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary opening upon the needs of the individual case. Any comments on the amount of time you are required to complete the should be sent to the Crief Information Officer, U.S. Patent and Trademark.

There, West-should be sent to the Crief Information Officer, U.S. Patent and Trademark.

There, West-should be to the Complete Trademark of the Comple

Please type a plus sign (+) inside this box -> +

PTO/SB/08A (08-00)

PTUVSUIVA (04-04)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to respond to a collection of information unless it contains a valid OMB control number

ns are required to respond to a collection of information unless it comains a value of the Complete if Known		
Application Number	USNP of PCT/EP2003/005224	
	19 May 2003 (19.05.2003)	
	Hiltrud LINDENBLATT ET AL.	
	unknown	
	unknown	
	MERCK-2955	
	Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number	

xaminer	Cite No.1	NON PATENT LITERATURE DOCUMENTS  Include name of the sulfnor (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, lound, storial, symposium, calledge, etc.), site, page(s), volume-issue number(s), publisher (sy anotic country where published lound, storial, symposium, calledge, etc.), site, page(s), volume-issue number(s), publisher (sy anotic country where published.	T2
Initials *		Journal, sortal, preposium, cutiong, etc.), sate, purpor, to- KAMIM, W. E. T.A., "EVALUATION OF ABSORPTION ENHANCEMENT FOR A POTENT CYCLOPPTIDIC ALPHA, NU. BETA-3-ANTAGONIST IN A HUMAN INTESTINAL CELL LINE(CACO- DY EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2000), 10(3), 205-214, SEITE 206, LINKE SPALTE, LETZTER ABSATZ, SEITE 208, LINKE SPALTE, ABSATZ 3; SEITE 213, LINKE SPALTE, ABSATZ 2-ASBATZ 3.	
	1		
	-		-
	-		-
	+-		+
	-		+-
			1

1	Examiner		Date Considered	
1	Signature	al if reference considered, whether or not citation is in conf	ormance with MPEF	609. Draw line through citation if not in conformance
	FYAMINER: Initi	al if reference considered, whether or manufaction to app	dicant.	

EXAMINER: Initial if reference considered, whether or not catalon is in communication and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark.

The Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office. Washington, D.C. 2023. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.